A tetrazine-responsive isonitrile-caged photosensitiser for site-specific photodynamic therapy.

J Control Release

Department of Chemistry, The Chinese University of Hong Kong, Shatin, N.T., Hong Kong, China. Electronic address:

Published: January 2023

We report herein a versatile and efficient bioorthogonal strategy to actualise targeted delivery and site-specific activation of photosensitisers for precise antitumoural photodynamic therapy. The strategy involved the use of an isonitrile-caged distyryl boron dipyrromethene-based photosensitiser, labelled as NC-DSBDP, of which the photoactivities could be specifically activated upon conversion of the meso ester substituent to carboxylate initiated by the [4 + 1] cycloaddition with a tetrazine derivative. By using two tetrazines conjugated with a galactose moiety or the GE11 peptide, labelled as gal-Tz and GE11-Tz, we could selectively label the cancer cells overexpressed with the asialoglycoprotein receptor and the epidermal growth factor receptor respectively. Upon encountering the internalised NC-DSBDP, these tetrazines triggered the "ester-to-carboxylate" transformation of this compound, activating its fluorescence and reactive oxygen species generation inside the target cells. The bioorthogonal activation was also demonstrated in vivo, leading to effective photo-eradication of the tumour in nude mice.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2022.12.015DOI Listing

Publication Analysis

Top Keywords

photodynamic therapy
8
tetrazine-responsive isonitrile-caged
4
isonitrile-caged photosensitiser
4
photosensitiser site-specific
4
site-specific photodynamic
4
therapy report
4
report versatile
4
versatile efficient
4
efficient bioorthogonal
4
bioorthogonal strategy
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!